Phase II company positioned for growth
Cereno Scientific is well-positioned for strong growth in an attractive cardiovascular and rare diseases market with a diversified portfolio of clinical and preclinical candidates.
A clinical phase II study is planned with CS1 for the treatment of the rare disease pulmonary arterial hypertension (PAH).
Therapeutics in common and rare cardiovascular disease
Cereno has a project portfolio targeting common and rare cardiovascular diseases. The aim is to develop treatments that can improve the life for affected patients. The portfolio comprises a Phase II program and two preclinical programs.
Epigenetic modulation in focus
Cereno combines an extensive experience in cardiovascular diseases with epigenetic modulation in a novel approach to developing new treatments for patients in need. The aim is to use epigenetic modulating to improve the health of cardiovascular patients, both in common and rare diseases.